GSEP
VKTX icon

Golden State Equity Partners’s Viking Therapeutics VKTX Stock Holding History

Golden State Equity Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-143
Closed -$4.65K – 1693
2026
Q1 		$4.65K Buy
+143
New +$4.6K ﹤0.01% 1487

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Golden State Equity Partners's VKTX Position: Q2 2026 in Review

Golden State Equity Partners sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 143 shares — an estimated $4.65K sold.

Golden State Equity Partners first reported a position in VKTX in Q1 2026 and held it in 1 quarter. The position peaked at $4.65K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Golden State Equity Partners reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 143 Viking Therapeutics shares in Q2 2026, an estimated $4.65K.
  • Golden State Equity Partners first reported a position in Viking Therapeutics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Viking Therapeutics position peaked at $4.65K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.